Inotiv provides Q1 2021 financials for Bolder BioPATH & HistoTox; CCO Flynn departs with severance

Inotiv, Inc.

Bolder BioPATH Q1 2021 net income $868K, revenue $3.74M; acquired for $18.5M cash, $1.5M notes, $34.5M in shares in May 2021.
HistoTox Labs Q1 2021 net income $962K, revenue $2.62M; acquired for $22.3M cash in April 2021.
Former CCO Joseph Flynn terminated Sep 8; severance includes 4-month salary continuation, COBRA reimbursement.
Flynn forfeits unvested options/RSUs, can exercise 7,000 options until Oct 8, 2021.
Non-solicitation obligation reduced from 24 to 6 months; mutual non-disparagement and release of claims.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph E. Flynn

Chief Commercial Officer

NOTV · Inotiv, Inc.

Effective: 2021-09-08
Filed: September 28, 2021, 7:59 PM ET

Inotiv, Inc. (the “Company”) and Joseph E. Flynn, the Company’s former Chief Commercial Officer, entered into an agreement (the “Separation and Release Agreement”) in connection with the termination of Mr. Flynn’s employment on September 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph E. Flynn was terminated as Chief Commercial Officer at Inotiv, Inc..

Action: terminated
Role: Chief Commercial Officer

Exact text from the filing

Inotiv, Inc. (the “Company”) and Joseph E. Flynn, the Company’s former Chief Commercial Officer, entered into an agreement (the “Separation and Release Agreement”) in connection with the termination of Mr. Flynn’s employment on September 8, 2021.

View on SEC.gov

Inotiv, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-21-012840

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.